Vor Biopharma Inc. Estimates – NASDAQ:VOR

Vor Biopharma (VOR) After TELIGAN Data Has An Undervalued Narrative Back In Focus

Vor Biopharma Inc. (VOR) stock price, news, quote and history

VOR Nov 2026 35.000 call (VOR261120C00035000) Interactive Stock Chart - Yahoo Finance

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

A kidney treatment was linked to 89% lower risk of a confirmed 30% kidney-function drop over two years.

Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint

Vor Biopharma (VOR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VOR

VOR Initiates Coverage On Vor Biopharma -- Rating "Outperform" b

William Blair Initiates Coverage On Vor Biopharma with Outperform Rating

Citi Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $50

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis